Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
iCAD, Inc. provides AI-powered cancer detection and breast health software for radiology providers, centered on the ProFound AI Breast Health Suite and ProFound Cloud. Company news has covered mammography workflow integrations, distribution and reseller partnerships, research presentations in breast cancer detection, risk evaluation, breast density assessment, and breast arterial calcification assessment, along with FDA clearance for ProFound Detection and periodic operating results.
iCAD's later corporate news and filings also document its transition from a Nasdaq-listed public company to a wholly owned subsidiary of RadNet following a completed merger in July 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
iCAD (NASDAQ: ICAD), a leader in cancer detection technology, announced a webinar featuring Dr. Kathy Schilling from Boca Raton Regional Hospital on May 24, 2023. The session will showcase how ProFound AI technology enables radiologists to detect 23% more cancers without increasing recall rates. This innovative AI tech, which is FDA-cleared, enhances sensitivity by 8% and reduces false positives and reading time significantly. Dr. Schilling's presentation will highlight clinical practices and case studies that underline the effectiveness of ProFound AI. This technology has shown remarkable improvements in mammography accuracy, demonstrating its essential role in modern healthcare.